Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

24.50USD
4:00pm EDT
Change (% chg)

$1.05 (+4.48%)
Prev Close
$23.45
Open
$23.20
Day's High
$24.65
Day's Low
$23.20
Volume
185,075
Avg. Vol
123,157
52-wk High
$27.90
52-wk Low
$14.95

Latest Key Developments (Source: Significant Developments)

Lannett receives two FDA approvals for Lansoprazole, one each for full prescription and OTC
Monday, 2 Oct 2017 06:56am EDT 

Oct 2 (Reuters) - Lannett Company Inc : :Lannett receives two fda approvals for Lansoprazole delayed-release capsules usp, one each for full prescription and OTC.Lannett Company Inc - co expect to commence marketing our prescription Lansoprazole delayed-release capsules product in next several months​.  Full Article

Lannett receives FDA approval for Oxycodone and Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg
Wednesday, 27 Sep 2017 06:51am EDT 

Sept 27 (Reuters) - Lannett Company Inc :Lannett receives FDA approval for Oxycodone And Acetaminophen tablets USP, 5 mg/325 mg and 10 mg/325 mg.Lannett Company Inc - ‍Expect to commence marketing drug along with other approved products in next several months​.  Full Article

Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg
Tuesday, 26 Sep 2017 06:53am EDT 

Sept 26 (Reuters) - Lannett Company Inc :Lannett receives approval for Dexmethylphenidate Hydrochloride tablets, 2.5 mg, 5 mg and 10 mg.Lannett Company Inc - ‍Anticipates launching Dexmethylphenidate Hydrochloride tablets in next several months​.Lannett Company Inc - ‍Dexmethylphenidate Hydrochloride tablets are used for treatment of attention deficit and hyperactivity disorder ​.  Full Article

Lannett announces dismissal of class action lawsuit
Tuesday, 26 Sep 2017 06:40am EDT 

Sept 26 (Reuters) - Lannett Company Inc ::Lannett announces dismissal of class action lawsuit.Lannett Company - judge dismissed in entirety putative class action lawsuit against a multitude of generic drug manufacturers including Lannett​.  Full Article

Lannett's board of directors initiates CEO search
Monday, 25 Sep 2017 06:54am EDT 

Sept 25 (Reuters) - Lannett Company Inc ::Lannett's board of directors initiates CEO search.Lannett Company Inc - ‍board has retained a leading executive search firm to identify potential candidates to assume role of CEO​.Lannett Company Inc - during search process, Bedrosian will remain a member of board of directors.Lannett company - after appointment of successor, expected that Bedrosian to remain with co in strategic advisory role.Lannett Company-filed a 505(b)(2) new drug application with U.S. FDA for cocaine hydrochloride topical solution​.  Full Article

Lannett Company - ‍Arthur Bedrosian, CEO has prevailed in his lawsuit with U.S. Internal Revenue Service​
Friday, 22 Sep 2017 06:53am EDT 

Sept 22 (Reuters) - Lannett Company Inc :Lannett Company Inc - ‍Arthur Bedrosian, CEO has prevailed in his lawsuit with U.S. Internal Revenue Service​.Lannett-Judge found Bedrosian was credible,did not willfully fail to identify one of two foreign accounts on report of foreign bank,financial accounts.  Full Article

Lannett Co reports Q4 adjusted earnings per share $0.40
Wednesday, 23 Aug 2017 04:24pm EDT 

Aug 23 (Reuters) - Lannett Company Inc :Lannett reports fiscal 2017 fourth-quarter and full-year financial results, provides guidance for fiscal 2018.Q4 adjusted earnings per share $0.40.Q4 earnings per share $0.15.Q4 sales $139.1 million versus I/B/E/S view $149.3 million.Q4 earnings per share view $0.55 -- Thomson Reuters I/B/E/S.Sees FY 2018 revenue $655 million to $665 million.Lannett Company Inc sees ‍ fiscal 2018 capital expenditures $65 million to $75 million​.FY2018 revenue view $646.5 million -- Thomson Reuters I/B/E/S.Lannett Company Inc sees fiscal 2018 GAAP gross margin 46% to 47% and adjusted gross margin 51% to 52%​.  Full Article

Lannett Co says expects Q4 2017 GAAP EPS $0.12 - $0.15
Tuesday, 8 Aug 2017 06:54am EDT 

Aug 8 (Reuters) - Lannett Company Inc :Lannett announces preliminary fiscal 2017 fourth-quarter and full-year financial results, comments on fiscal 2018 outlook.Lannett Company Inc - for fiscal 2017 Q4, net sales and total net sales are expected to be approximately $139 million.Sees Q4 2017 GAAP earnings per share $0.12 to $0.15.Sees Q4 2017 adjusted earnings per share $0.37 to $0.40.Lannett Company Inc - ‍on track to submit a new drug application for proprietary C-Topical product shortly​.Q4 earnings per share view $0.75, revenue view $162.8 million -- Thomson Reuters I/B/E/S.Lannett Company Inc - ‍expected launch of 10 already approved products in coming fiscal year​.Lannett Company Inc - ‍for fiscal 2018 expect "solid increase" to topline versus fiscal 2017 and adjusted gross margin to continue to be above 50 percent​.Lannett - based on prelim results for 2017,are "well within" co's debt financial covenants, expect to meet these requirements for foreseeable future​.  Full Article

Lannett receives approval for Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL
Friday, 14 Jul 2017 06:53am EDT 

July 14 (Reuters) - Lannett Company Inc :Lannett receives approval for cyproheptadine hydrochloride syrup, 2 mg/5 ml.Lannett company inc - ‍product was previously marketed under brand name periactin syrup, 2 mg/5 ml of merck and co., inc.​.  Full Article

Lannett receives approval for additional dosage strengths of hydrocodone bitartrate and acetaminophen tablets usp
Monday, 26 Jun 2017 06:51am EDT 

June 26 (Reuters) - Lannett Company Inc ::Lannett receives approval for additional dosage strengths of hydrocodone bitartrate and acetaminophen tablets usp.Lannett Company Inc - plan to launch all of recently approved products in new fiscal year, which begins next week.Lannett Company-received approval from FDA of anda for hydrocodone bitartrate and acetaminophen tablets usp, 5 mg/325 mg, 7.5 mg/325 mg, 10 mg/325 mg.  Full Article

BRIEF-Lannett receives two FDA approvals for Lansoprazole, one each for full prescription and OTC

* Lannett receives two fda approvals for Lansoprazole delayed-release capsules usp, one each for full prescription and OTC